Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
HERON THERAPEUTICS, INC. (HRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates • Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raise • Favorable outcome at Markman hearing in pending CINVANTI® ANDA patent litigation • New management team in place • Reiterating full-year net product sales guidance for the oncology care franchise of $99-$103 million SAN DIEGO, August 14, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and six months ended June 30, 2023 and highlig..."
07/24/2023 8-K Quarterly results
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HERON THERAPEUTICS, INC. Heron Therapeutics, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware , does hereby certify: FIRST: That, upon the Effective Time, Section A of Article IV of the Certificate of Incorporation of the Corporation shall be amended and restated in its entirety as follows: “A. Authorized Capital. The Corporation is authorized to issue two classes of shares of stock to be designated, respectively, “preferred” and “common.” The total number of shares that the Corporation is authorized to issue is Two Hundred Twenty-Seven Million Five Hundred Thousand . The number of shares of common stock authorized to be issued is Two ...",
"Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer SAN DIEGO, June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of William Forbes, Pharm.D., as Executive Vice President, Chief Development Officer. In addition, Kimberly Manhard, Heron’s Executive Vice President, Drug Development, has resigned from her position. Dr. Forbes joins Heron’s management team and will be responsible for leading clinical and product development for Heron’s acute care and oncology care franchises. “I am thrilled to welcome Bill to the Heron team a..."
05/11/2023 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates • Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022 • Appointment of Craig Collard as Chief Executive Officer and Jason Grillot as Vice President , Sales and Marketing, of the Acute Care Franchise. SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates. First quarter 2023 net product s..."
04/20/2023 8-K Quarterly results
04/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Heron Therapeutics Announces New CEO and Board Chairman Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board SAN DIEGO, April 3, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the appointment of Craig Collard as Chief Executive Officer , effective today. Mr. Collard succeeds Barry Quart, Pharm.D., who has stepped down as CEO and Chairman of the Board. In addition, as part of the leadership change, the Board elected Adam Morgan as Chairman. Mr. Collard brings more than three decades of experience leading innovative pharmaceutical companies through periods of strategic change to deliver growth ..."
03/23/2023 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates - Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product Sales in 2021 - - APONVIE™Commercially Launched on March 6, 2023 - - ZYNRELEF® Net Product Sales for Fourth Quarter of 2022 Increased 44% Over Prior Quarter to $3.9 Million - - Oncology Care Franchise Net Product Sales for 2022 Grew 17% Over Prior Year to $97.5 Million – SAN DIEGO, March 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results ..."
03/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Heron Therapeutics Announces Centers for Medicare & Medicaid Services Granted Pass-through Payment Status for APONVIETM, Effective April 1, 2023 SAN DIEGO, March 13, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that CMS has approved transitional pass-through status for APONVIE injectable emulsion, which will be established for three years beginning April 1, 2023 under C-code C9145. APONVIE was approved by the U.S. Food and Drug Administration for intravenous use in adults for the prevention of postoperative nausea and vomiting and became commercially available on March 6, 2023. CMS grants pas..."
03/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Heron Therapeutics Announces U.S. Commercial Launch of APONVIETM for the Management of Postoperative Nausea and Vomiting in Adults - APONVIE, the first and only intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for Postoperative Nausea and Vomiting - - APONVIE is delivered via a single IV push and offers 48 hours of PONV prevention - - Leveraging existing acute care commercial teams across the U.S. - SAN DIEGO, March 6, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced APONVIE injectable emulsion, is now commercially available for intravenous use in adults for the..."
02/22/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cooperation Agreement, by and among Heron Therapeutics, Inc., Rubric Capital Management LP, the persons and entities listed on Schedule A thereto, Velan Capital Investment Management LP, and the persons and entities listed on Schedule B thereto",
"Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital"
01/09/2023 8-K Quarterly results
12/29/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
Docs: "®"
09/19/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Press Release",
"Corporate Presentation"
08/10/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/25/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF® from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care",
"Corporate Presentation"
03/17/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "About ZYNRELEF ® for Postoperative Pain"
02/28/2022 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates - ZYNRELEF ® has received 260 formulary approvals since initial launch in July 2021, with over a 90% hospital approval rate and over 60% of approvals have been for unrestricted usage -"
12/09/2021 8-K Quarterly results
11/18/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA"
11/03/2021 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates - ZYNRELEF ® net product sales of $2.1 million in its first quarter of launch with 160 unique accounts already purchasing ZYNRELEF and 50% of those accounts reordering -"
10/04/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "can increase the risk of a heart attack or stroke that can lead to death. This risk increases with higher doses and longer use of an NSAID. • cannot be used during heart bypass surgery. • can increase the risk of gastrointestinal bleeding, ulcers, and tears. ZYNRELEF should also not be used if you are allergic to any components of ZYNRELEF, aspirin or other NSAIDs , or have had an asthma attack, hives, or other allergic reaction after taking any of these medicines; or as a paracervical block, during childbirth. The most common side effects of ZYNRELEF are constipation, vomiting, and headache. The medicines in ZYNRELEF can affect the nervous and cardiovascular system; may cause liver or kidney problems; may reduce the effects of some blood pressure medicines; should be avoided if you have s..."
09/24/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
08/02/2021 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "Letter from OUM"
06/17/2021 8-K Quarterly results
05/25/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy